Illumina, Inc.

ILLUMINA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Illumina, Inc. and Encourages Investors to Contact the Firm

Retrieved on:

Thursday, November 16, 2023

Class Action Lawsuit, Professional Services, Legal, Defendant, Acquisition, GRAIL, Telephone, Complaint, Illumina, Inc., Jeanne Eagels, Icahn, District court, Person, P.C, Court, News, Cryptocurrency, Reuters, Illumina

Investors have until January 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until January 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
Then, on October 17, 2023, Carl Icahn (“Icahn”) filed a complaint against current and former directors of Illumina, alleging direct and derivative claims of breaches of fiduciary duty.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Illumina, Inc. (ILMN) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against Illumina, Inc.

Retrieved on:

Wednesday, November 15, 2023

Class Action Lawsuit, Professional Services, Legal, Acquisition, GRAIL, LLP, Complaint, Illumina, Inc., European, Person, ILMN, News, Cryptocurrency, Reuters, Illumina, Inc.

Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Illumina, Inc. (NASDAQ: ILMN) securities between May 1, 2023 and October 16, 2023.

Key Points:

Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Illumina, Inc. (NASDAQ: ILMN) securities between May 1, 2023 and October 16, 2023.
For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
After GRAIL raised $1.9 billion through venture capital and strategic partners, Illumina announced plans to reacquire GRAIL in September 2020.
What Now: Similarly situated shareholders may be eligible to participate in the class action against Illumina, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Illumina, Inc. (ILMN) Investors

Retrieved on:

Tuesday, November 14, 2023

Class Action Lawsuit, Professional Services, Legal, GRAIL, Acquisition, LLP, Complaint, Illumina, Inc., Icahn, District court, Court, News, Tobacco, Reuters, Illumina

Investors have until January 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points:

Investors have until January 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.
Additional information about the firm can be found at Kirby McInerney LLP’s website: https://www.kmllp.com .

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Illumina, Inc. (ILMN) Investors

Retrieved on:

Monday, November 13, 2023

Class Action Lawsuit, Professional Services, Legal, Defendant, Suite, Acquisition, GRAIL, Telephone, Law, Complaint, Illumina, Inc., Icahn, News, Cryptocurrency, Reuters, Illumina

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN ) securities between May 1, 2023 and October 16, 2023, inclusive (the “Class Period”).

Key Points:

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN ) securities between May 1, 2023 and October 16, 2023, inclusive (the “Class Period”).
Illumina investors have until January 9, 2024 to file a lead plaintiff motion.
Investors suffering losses on their Illumina investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Illumina Announces Decision to Divest GRAIL

Retrieved on:

Sunday, December 17, 2023

Sale, GRAIL, SAN, Security (finance), European Commission, Justice, Risk, Civil service commission, Patient, Illumina, Inc., Federal Trade Commission, Form 10-K, European Court of Justice, Court, European Court, Illumina

SAN DIEGO, Dec. 17, 2023 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL.

Key Points:

SAN DIEGO, Dec. 17, 2023 /PRNewswire/ -- Today, Illumina, Inc. (NASDAQ: ILMN) announced that the company will divest GRAIL.
On December 15, the U.S. Fifth Circuit Court of Appeals issued its decision in the matter of Illumina v. the Federal Trade Commission.
Following a review of the Court's opinion, Illumina has elected not to pursue further appeals of the Fifth Circuit's decision.
As the company has previously stated, if it was not successful with either its European Court of Justice jurisdictional appeal or in a final decision of the Fifth Circuit, it would divest GRAIL.

$3.34 Billion DNA Data Storage (Cloud, On-Premises) Markets, 2030: Focus on Sequence-based DNA Data Storage, Structure-based DNA Data Storage

Retrieved on:

Friday, December 15, 2023

DUBLIN, Dec. 15, 2023 /PRNewswire/ -- The "DNA Data Storage Market by Type (Cloud, On-Premises), Technology (Sequence-based DNA Data Storage, Structure-based DNA Data Storage), End Users (Government, Healthcare & Biotechnology, Media & Telecommunication) and Geography - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points:

DUBLIN, Dec. 15, 2023 /PRNewswire/ -- The "DNA Data Storage Market by Type (Cloud, On-Premises), Technology (Sequence-based DNA Data Storage, Structure-based DNA Data Storage), End Users (Government, Healthcare & Biotechnology, Media & Telecommunication) and Geography - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
The rising demand for big data applications is one of the key driving factors for the DNA data storage market.
DNA data storage is more durable than traditional data storage solutions, meaning that data centres can reduce their spending on hardware replacement.
Sequence-based DNA data storage is a type of DNA data storage in which data is encoded in the sequence of DNA bases.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Illumina, Inc. (ILMN) Investors

Retrieved on:

Friday, November 10, 2023

Class Action Lawsuit, Professional Services, Legal, Defendant, Suite, Acquisition, GRAIL, Law, Complaint, Illumina, Inc., Icahn, Person, Court, News, Cryptocurrency, Reuters, Illumina

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN ) securities between May 1, 2023 and October 16, 2023, inclusive (the “Class Period”).

Key Points:

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Illumina, Inc. (“Illumina” or the “Company”) (NASDAQ: ILMN ) securities between May 1, 2023 and October 16, 2023, inclusive (the “Class Period”).
Illumina investors have until January 9, 2024 to file a lead plaintiff motion.
If you are a shareholder who suffered a loss, click here to participate.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

ILMN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc.

Retrieved on:

Friday, November 10, 2023

Class Action Lawsuit, Professional Services, Legal, Defendant, Suite, Acquisition, GRAIL, Complaint, Illumina, Inc., GPM, Icahn, District court, Person, Court, News, Medical device, Cryptocurrency, Reuters, Illumina

Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).

Key Points:

Plaintiff pursues claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”).
Investors are hereby notified that they have 60 days from the date of this notice to move the Court to serve as lead plaintiff in this action.
To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

In-vitro Diagnostics Market to grow by USD 33.16 billion from 2021 to 2026 | The rising geriatric population with chronic and infectious diseases drives the market growth - Technavio

Retrieved on:

Wednesday, December 13, 2023

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.

Key Points:

NEW YORK, Dec. 12, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.
The rising geriatric population with chronic and infectious diseases drives the in-vitro diagnostics (IVD) market growth during the forecast period.
Hence, the increasing prevalence of diseases in the aging population is expected to drive market growth during the forecast period.
Key challenges - Stringent regulatory guidelines for in-vitro diagnostics manufacturers can pose a significant threat which can hinder the in-vitro diagnostics (IVD) market growth during the forecast period.

In-vitro Diagnostics Market to grow by USD 33.16 billion from 2021 to 2026| The rising geriatric population with chronic and infectious diseases drives the market growth- Technavio

Retrieved on:

Monday, December 4, 2023

NEW YORK, Dec. 3, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.

Key Points:

NEW YORK, Dec. 3, 2023 /PRNewswire/ -- The in-vitro diagnostic market size is estimated to grow by USD 33.16 billion from 2021 to 2026.
The rising geriatric population with chronic and infectious diseases drives the in-vitro diagnostics (IVD) market growth during the forecast period.
Hence, the increasing prevalence of diseases in the aging population is expected to drive market growth during the forecast period.
The in-vitro diagnostics market report provides critical information and factual data, with a qualitative and quantitative study of the market based on market drivers and limitations as well as future prospects.